
Novo Nordisk (NYSE:NVO) would be open to considering a direct listing of its shares on the New York Stock Exchange, Chief Executive Mike Doustdar told the Financial Times in an interview published Wednesday. Doustdar said he could see advantages to such a move when asked about the possibility, although he clarified that the Danish pharmaceutical company is not currently exploring a change to its U.


























